FTC v. Endo Pharmaceuticals (Pay-for-Delay)

Lidoderm patches treat localized pain. When patents neared expiry, generic drug makers filed FDA applications to sell cheaper copies—potentially saving patients and insurers millions.

Instead of fighting in court to a finish, brand manufacturer Endo allegedly struck 'reverse payment' settlements: paying generic firms to delay launch years in exchange for sharing profits.

The FTC calls these 'pay-for-delay' deals unfair methods of competition under Section 5 and antitrust law. Consumers keep paying brand prices while generics wait in the wings.

The Supreme Court's 2013 Actavis decision said such settlements can violate antitrust law when large cash payments suggest anti-competitive purpose—not every settlement, but suspicious ones face scrutiny.

FTC's Endo complaint targeted Lidoderm agreements with Watson/Teva affiliates as exemplifying the practice across pharma.

Endo settled in 2016, agreeing to avoid certain settlement structures—adding to a string of FTC pharma enforcement actions.

The case matters for anyone filling prescriptions: delayed generics translate directly into higher copays and insurance premiums.

Generic delay keeps drug bills high after patents should expire.

FTC uses Section 5 alongside Sherman Act theories.

Settlements can reform industry practices without trial.

Reverse payments protected Endo's monopoly unlawfully.

Generic entry was delayed without pro-competitive justification.

Consumers and payers overpaid for patches.

Pharma argued settlements avoid costly litigation uncertainty.

Endo settled without admitting wrongdoing.

Ask pharmacists about generic availability—delays may be legal fights, not science.

Employer health plans bear pay-for-delay costs too.